Skip to main content

Advertisement

SpringerLink
Log in

Renal Denervation for Resistant Hypertension: Where Do We Stand?

  • Resistant Hypertension (L Drager, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review the data about the use of renal denervation (RDN), a minimally invasive surgery, for resistant hypertension (RH) and to provide practical guidance for practitioners who are establishing an RDN service.

Recent Findings

RDN can selectively ablate renal sympathetic nerve fibres, block the transmission of nerve impulses between central sympathetic nerve and kidney, to control blood pressure to as a novel promising non-drug treatment option for RH. At present, there are many researches on the treatment of RH by RDN, but there are some controversies. This review summarises and critically examines the evidence for RDN in the treatment of RH and identifies areas for future research.

Summary

With the development of RDN, the continuous innovation of RDN technology and methods, the development about better evaluating the real-time success of RDN and the improvement for identifying individuals who are most likely to benefit from RDN will ultimately determine whether RDN represents a feasible way to manage RH in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

Not applicable.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Lay-Flurrie SL, Sheppard JP, Stevens RJ, Mallen C, Heneghan C, Hobbs FDR, et al. Impact of changes to National Hypertension Guidelines on hypertension management and outcomes in the United Kingdom. Hypertension. 2020;75(2):356–64 This paper emphasizes the importance of out-of-office blood pressure monitoring diagnosis of hypertension.

    CAS  PubMed  Google Scholar 

  2. Collaboration NCDRF. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389(10064):37–55.

    Google Scholar 

  3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.

    PubMed  Google Scholar 

  4. •• Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115 This comprehensive guideline statement, which will have a major influence on the evaluation and management of hypertension in the USA, emphasizes the importance of out-of-office blood pressure measurement in establishing the diagnosis of hypertension and in assessing the effects of therapy.

    CAS  PubMed  Google Scholar 

  5. • Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355–61 This systematic review concludes prevalence of resistant hypertension in treated hypertensive populations.

    PubMed  Google Scholar 

  6. Hayes P, Casey M, Glynn LG, Molloy GJ, Durand H, O'Brien E, et al. Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care. Br J Gen Pract. 2018;68(671):e394–400.

    PubMed  PubMed Central  Google Scholar 

  7. Smith SM, Gurka MJ, Winterstein AG, Pepine CJ, Cooper-DeHoff RM. Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. J Clin Hypertens. 2019;21(6):825–34.

    CAS  Google Scholar 

  8. Kaczmarski KR, Sozio SM, Chen J, Sang Y, Shafi T. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES). BMC Nephrol. 2019;20(1):138.

    PubMed  PubMed Central  Google Scholar 

  9. Sinnott S-J, Smeeth L, Williamson E, Douglas IJ. Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995–2015. BMJ. 2017;358:j3984.

    PubMed  PubMed Central  Google Scholar 

  10. Smithwick RH. Hypertensive vascular disease; results of and indications for splanchnicectomy. J Chronic Dis. 1955;1(5):477–96.

    CAS  PubMed  Google Scholar 

  11. White PD. Severe hypertension; study of one hundred patients with cardiovascular complications; follow-up results in fifty controls and fifty patients subjected to Smithwick's lumbodorsal sympathectomy, 1941 to 1946. J Am Med Assoc. 1956;160(12):1027–8.

    CAS  PubMed  Google Scholar 

  12. McGregor AL. Essential hypertension, a five-year follow-up of operated cases. S Afr Med J. 1952;26(10).

  13. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic- nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932–4.

    CAS  PubMed  Google Scholar 

  14. • Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81 This paper concludes catheter-based renal denervation causes substantial and sustained blood-pressure reduction, without serious adverse events, in patients with resistant hypertension.

    PubMed  Google Scholar 

  15. •• Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071–8 This trial demonstrates no benefit of renal artery denervation on reduction in ambulatory blood pressure in either the 24-h or day and night periods compared with sham.

    PubMed  Google Scholar 

  16. •• Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–51 This parper indicates the superiority of catheter-based renal denervation compared with a sham procedure to safely lower blood pressure in the absence of antihypertensive medications.

    PubMed  Google Scholar 

  17. • Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9 Six-month results of Symplicity HTN-2.

    PubMed  Google Scholar 

  18. • Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–82 One-year results of Symplicity HTN-2.

    CAS  PubMed  Google Scholar 

  19. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.

    CAS  PubMed  Google Scholar 

  20. •• Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D’Agostino R, et al. 12- month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21 This parper supports no further reduction in office or ambulatory blood pressure after 1-year follow-up.

    PubMed  Google Scholar 

  21. •• Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9 Three-year results of Symplicity HTN-2 (Renal denervation resultes in sustained lowering of blood pressure at 3 years in a selected population of subjects with severe, treatment-resistant hypertension without serious safety concerns).

    PubMed  PubMed Central  Google Scholar 

  22. •• Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7 This parper shows catheter-based renal sympathetic denervation results in a substantial reduction in blood pressure sustained out to more than 2 years of follow-up, in patients with resistant hypertension, without significant adverse events.

    Google Scholar 

  23. • Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9 Three-year results of Symplicity HTN-1.

    PubMed  Google Scholar 

  24. •• Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015;79(6):1222–9 SYMPLICITY HTN-Japan is underpowered for the primary endpoint analysis and demonstrates no significant difference in 6-month blood pressure change between renal artery denervation and control subjects.

    CAS  PubMed  Google Scholar 

  25. •• Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34(28):2132–40 Renal sympathetic denervation results in a rapid and significant office blood pressure reduction that is sustained through 6 months.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. •• Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, et al. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension. 2014;64(3):565–72 The 12-month data continue to demonstrate safety and efficacy of the EnligHTN ablation system in patients with drug- resistant hypertension.

    CAS  PubMed  Google Scholar 

  27. Pio-Abreu A, Drager LF. Resistant hypertension: time to consider the best fifth anti-hypertensive treatment. Curr Hypertens Rep. 2018;20(8):67.

    PubMed  Google Scholar 

  28. •• Verheye S, Ormiston J, Bergmann MW, Sievert H, Schwindt A, Werner N, et al. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study. EuroIntervention. 2015;10(10):1221–9 This parper demonstrates safe delivery of radiofrequency energy by the OneShot Renal Denervation System for renal sympathetic denervation and sustained efficacy, as evidenced by a significant reduction in office and 24-hour ambulatory blood pressure monitoring for six months, which was sustained up to 12 months.

    PubMed  Google Scholar 

  29. •• Worthley SG, Wilkins GT, Webster MW, Montarello JK, Delacroix S, Whitbourn RJ, et al. Safety and performance of the second generation EnligHTNTM Renal Denervation System in patients with drug-resistant, uncontrolled hypertension. Atherosclerosis. 2017;262:94–100 Renal sympathetic denervation using the second generation EnligHTN Renal Denervation System resulted in safe, rapid, and significant mean office blood pressure reduction that was sustained through 24 months.

    CAS  PubMed  Google Scholar 

  30. •• Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention. 2015;10(10):1213–20 Renal artery denervation with the Vessix System reduces both office and ambulatory blood pressure at six months in patients with resistant hypertension. Renal artery safety and renal function results are favourable.

    PubMed  Google Scholar 

  31. •• Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65 In patients with well defined resistant hypertension, renal denervation plus an standardised stepped-care antihypertensive treatment decreases ambulatory blood pressure more than the same standardised stepped-care antihypertensive treatment alone at 6 months. This additional blood pressure lowering effect may contribute to a reduction in cardiovascular morbidity if maintained in the long term after renal denervation.

    PubMed  Google Scholar 

  32. • Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70 Results from SPYRAL HTN-OFF MED provide biological proof of principle for the blood-pressure-lowering efficacy of renal denervation.

    PubMed  Google Scholar 

  33. •• Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55 Renal denervation in the main renal arteries and branches significantly reduced blood pressure compared with sham control with no major safety events. Incomplete medication adherence was common.

    PubMed  Google Scholar 

  34. •• Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE- HTN SOLO): a multicentre, international, single-blind, randomised, sham- controlled trial. Lancet. 2018;391(10137):2335–45 Compared with a sham procedure, endovascular ultrasound renal denervation reduced ambulatory blood pressure at 2 months in patients with combined systolic-diastolic hypertension in the absence of medications.

    PubMed  Google Scholar 

  35. • Li Y, Nawabi AQ, Feng Y, Dai Q, Ma G, Liu N. Safety and efficacy of a new renal denervation catheter in hypertensive patients in the absent of antihypertensive medications: a pilot study. Int J Hypertens. 2019;2019:7929706 The new renal denervation system is safe and could significantly reduce blood pressure in hypertensive patients in the absence of antihypertensive medications.

    PubMed  PubMed Central  Google Scholar 

  36. •• Oliveras A, Armario P, Clarà A, Sans-Atxer L, Vázquez S, Pascual J, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863–71 Spironolactone is more effective than renal denervation to reduce 24-h systolic and diastolic blood pressure in patients with resistant hypertension.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. • Oliveras A, Armario P, Sans L, Clarà A, Vázquez S, Molina L, et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervación en Hipertensión Arterial) study. J Clin Hypertens. 2018;20(1):69–75 At 6 months there was a reduction in albuminuria in patients with resistant hypertension treated with spironolactone as compared with renal denervation.

    CAS  Google Scholar 

  38. •• de la Sierra A, Pareja J, Armario P, Barrera Á, Yun S, Vázquez S, et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. Am J Hypertens. 2017;30(1):37–41 Spironolactone is more effective than sympathetic renal denervation in reducing ambulatory blood pressure. However, blood pressure variability is significantly more reduced with sympathetic renal denervation.

    PubMed  Google Scholar 

  39. •• Rosa J, Widimsk’ P, Toušek P, Petrák O, Čurila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague- 15 study. Hypertension. 2015;65(2):407–13 Renal denervation achieved reduction of blood pressure comparable with intensified pharmacotherapy.

    CAS  PubMed  Google Scholar 

  40. •• Rosa J, Widimsk’ P, Waldauf P, Lambert L, Zelinka T, Táborsk’ M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2016;67(2):397–403 Spironolactone addition (if tolerated) seems to be more effective in blood pressure reduction.

    CAS  PubMed  Google Scholar 

  41. • Rosa J, Widimsk’ P, Waldauf P, Zelinka T, Petrák O, Táborsk’ M, et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. J Hypertens. 2017;35(5):1093–9 Spironolactone addition (if tolerated) seems to be of better efficacy than renal denervation in blood pressure reduction over a period of 24 months.

    CAS  PubMed  Google Scholar 

  42. Liu Z, Shen L, Huang W, Zhao X, Fang W, Wang C, et al. Efficacy and safety of renal denervation for Chinese patients with resistant hypertension using a microirrigated catheter: study design and protocol for a prospective multicentre randomised controlled trial. BMJ Open. 2017;7(9):e015672.

    PubMed  PubMed Central  Google Scholar 

  43. •• Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, et al. Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN trial. J Hum Hypertens. 2017;31(5):366–8 The REDUCE-HTN study suggests persistent blood pressure reductions in patients with resistant hypertension who were treated with the Vessix Renal Denervation System.

    CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China [81774229], Jiangsu Leading Talent Project of Traditional Chinese Medicine [Jiangsu TCM 2018 No. 4], Major Project of Nanjing Medical Science and Technology Development During 13th Five-year Plan [ZDX16013], and Jiangsu Universities Nursing Advantage Discipline Project [2019YSHL095].

Author information

Authors and Affiliations

  1. Nanjing University of Chinese Medicine, Nanjing, China

    Bo Liang

  2. Hospital (T.C.M.) Affiliated to Southwest Medical University, Luzhou, China

    Yu-Xiu Zhao

  3. Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China

    Ning Gu

Authors
  1. Bo Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Xiu Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ning Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ning Gu.

Ethics declarations

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Code Availability

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Resistant Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, B., Zhao, YX. & Gu, N. Renal Denervation for Resistant Hypertension: Where Do We Stand?. Curr Hypertens Rep 22, 83 (2020). https://doi.org/10.1007/s11906-020-01094-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-020-01094-6

Keywords

Search

Navigation